Investors should capitalize on the current "Memory Trade" momentum through Micron Technology (MU), though they must remain vigilant for a cyclical peak and potential oversupply. BioCryst Pharmaceuticals (BCRX) represents a high-conviction value play with a price target of $28, driven by the long-term potential of its rare disease pipeline. Conversely, Intel (INTC) is a prime short candidate or pair-trade laggard due to its weak AI positioning and unimpressive revenue growth compared to competitors. Avoid Sharon AI entirely, as misleading claims regarding NVIDIA (NVDA) ownership serve as a significant red flag for potential fraud. For diversified exposure to the semiconductor supercycle, maintain positions in leaders like Broadcom (AVGO) and Applied Materials (AMAT) while seeking international alpha in Japanese plays like Kioxia.

Micron Technology (MU)

• Context: Shkreli highlighted Micron's recent "blowout numbers" and noted the stock is trading at all-time highs. He categorized Micron as a "good" company (compared to NVIDIA as "great" and Intel as "not good").
• Sector Sentiment: Extremely bullish on the "Memory Trade." He noted that some memory stocks have seen 20x to 30x returns recently.
• Market Cap: Mentioned the company is approaching a $1.4 trillion market valuation, overtaking companies like Meta and Tesla.

Takeaways

• Capitalize on Momentum: The "Memory Trade" is currently described as "out of control" and "bananas."
• Risk of Cyclicality: Shkreli warned that while the current environment is excellent, hardware cycles typically lose their luster after a couple of years. He questioned if "this time is different" due to AI or if a classic oversupply is looming.
• Action: Consider Micron as a leading play in the memory sector, but remain wary of the cyclical peak.

Intel (INTC)

• Context: Shkreli expressed significant skepticism regarding Intel’s recent rally, calling it "suspect" because Intel is not a major player in AI.
• Fundamentals: He noted revenue growth is only around 7-11%, which he considers unimpressive for a "turnaround" story. He also pointed out that Intel's foundry business is currently "non-existent" compared to Taiwan Semiconductor (TSMC).
• Financial Observation: Noted an unusual "capital lease" structure on their cash flow statement and mentioned that CapEx is still down significantly from generational highs.

Takeaways

• Short Opportunity: Shkreli suggested Intel could be a good short candidate, specifically as a "pair trade" against stronger semiconductor companies.
• Avoid the "Vibe" Trade: While the broader market is rallying, Intel’s fundamentals do not currently support a high valuation in his view.

BioCryst Pharmaceuticals (BCRX)

• Context: Shkreli performed a live deep-dive into this biotech firm. The company focuses on Hereditary Angioedema (HAE).
• Key Assets:
  • Orladeyo: Their main drug, currently generating ~$150M/quarter.
  • Avotagabart (BCX17725): A phase 3 candidate that Shkreli believes could be a category leader due to its dosing profile (every 3 or 6 months).
• Valuation: He estimated a fair stock price of $28 (currently trading around $10).

Takeaways

• Bullish Outlook: Shkreli is officially bullish on BCRX, citing a $2 billion market cap that he believes is significantly undervalued based on the potential of their pipeline.
• Timeline: Reminded investors that biotech is a game of "years, not days."

Kioxia (Japanese Stock / Formerly Toshiba Memory)

• Context: Referred to as "Yoxa" or "Keoxia" in the transcript. Shkreli called this stock a "monster."
• Price Action: It traded at 3,000 yen for a long time and recently exploded to 104,000 yen.
• Insight: He used this as an example of why investors need to look at international markets for "alpha" (excess returns), noting that most people missed it because it is a Japanese listing.

Takeaways

• International Exposure: Investors should look beyond US exchanges (like Robinhood) to access international semiconductor/memory plays.

Abivax (ABVX)

• Context: Shkreli reiterated his long-standing bullish stance on this biotech company.
• Sentiment: He urged patience, stating that the story is still unfolding and he remains "all in."

Takeaways

• Hold Position: No new update other than maintaining a high-conviction bullish stance.

Sharon AI (Private/Unlisted)

• Context: Shkreli flagged this company as a potential "scam" or fraud.
• Red Flags: The company reportedly claimed in an SEC filing that NVIDIA was a strategic shareholder, only to retract the statement in a later filing (8-K) admitting NVIDIA holds no equity.
• Management: He expressed extreme distrust of the CEO, James Manning.

Takeaways

• Avoid/Short: He expressed a desire to short this company if possible, citing the misleading NVIDIA claims as a major warning sign of securities fraud.

Investment Themes & Sectors

The "Memory" and "Semiconductor" Supercycle

• Theme: AI is driving unprecedented demand for hardware.
• Sentiment: Frothy/Bubblicious.
• Key Tickers Mentioned: NVIDIA (NVDA), Broadcom (AVGO), Qualcomm (QCOM), Applied Materials (AMAT), Western Digital (WDC), and Seagate (STX).
• Risk: Shkreli warned of "classic oversupply" that usually follows hardware booms, though he admitted the AI cycle might delay this.

Private vs. Public Markets

• Theme: Shkreli argued that the "biggest companies in the world" now include private entities like SpaceX, OpenAI, Anthropic, and Stripe.
• Insight: He believes traditional stock screeners (like Finviz) are becoming obsolete because they ignore the massive valuation shifts happening in private AI and fintech firms.

Biotech Strategy

• Theme: Focus on "rare disease" drugs with long patent lives (e.g., until 2035).
• Sentiment: Bullish on Spruce Biosciences (SPRB) and Liquidia (LQDA) (historical pick), alongside the new interest in BioCryst (BCRX).